Key facts
- This page summarizes Scott B. Brown's Form 4 filing for Tracon Pharmaceuticals, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Mar 2024, 17:59.
Scott B. Brown - 12 Mar 2024 Form 4 Insider Report for Tracon Pharmaceuticals, Inc.
- Reporting relationship
- CHIEF FINANCIAL OFFICER
- Issuer ticker
- N/A
- Reported as of
- 12 Mar 2024
- Net transaction value
- +$482
- SEC form
- 4
- Accepted by SEC
- 13 Mar 2024, 17:59:38 UTC
- Prior SEC filing
- 03 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Scott B. Brown
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Scott B. Brown filed Form 4 for Tracon Pharmaceuticals, Inc. on 13 Mar 2024.
Change
- Previous filing in this sequence was filed on 03 Feb 2023.
- Current net transaction value: +$482.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TCON
transaction
Common Stock
Award
- Transaction value
- $482
- Shares
- +3,500
- Change %
- +16%
- Price
- $0.1377
- Shares after
- 25,128
- Date
- 20 Apr 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TCON
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +224,800
- Change %
- Price
- $0.000000
- Shares after
- 224,800
- Date
- 12 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 224,800
- Exercise price
- $0.3900
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on April 20, 2023.
Footnote F2
1/4th of the shares subject to this option shall vest on the first anniversary of the Grant Date shown in column 3 above. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter, on the last day of each month.